How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,688 results for

Nutrition in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Early enteral nutrition and total parenteral nutrition on the nutritional status and blood glucose in patients with gastric cancer complicated with diabetes mellitus after radical gastrectomy Full Text available with Trip Pro

Early enteral nutrition and total parenteral nutrition on the nutritional status and blood glucose in patients with gastric cancer complicated with diabetes mellitus after radical gastrectomy Effects of early enteral nutrition (EEN) or total parenteral nutrition (TPN) support on nutritional status and blood glucose in patients with gastric cancer complicated with diabetes mellitus after radical gastrectomy were investigated. One hundred and twenty-nine patients with gastric cancer complicated (...) with diabetes mellitus type 2 admitted to the First People's Hospital of Jinan (Jinan, China), from June 2012 to June 2016 were selected into the study. According to different nutrition support pathways, these patients were randomly divided into the EEN group and the TPN group. The improvement of nutritional indexes, postoperative complications, gastrointestinal function recovery and perioperative blood glucose fluctuation were compared between the two groups. On the 4th day after operation, the improvement

2018 Experimental and therapeutic medicine Controlled trial quality: uncertain

2. Management of Type 2 Diabetes Mellitus

threshold for initiating therapy, but delaying use until age 40 or later may be reasonable if patients do not have other cardiovascular risk factors. Statins may not be appropriate in some patients with diabetes, especially those with severe, chronic malnutrition from pancreatic insufficiency or women planning pregnancy. When deciding to start a statin, consider the 23 UMHS Management of Type 2 Diabetes Mellitus June, 2017 patient’s 10 year ASCVD risk, nutritional status and life expectancy. Low HDL (...) Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research

2020 University of Michigan Health System

3. Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

diabetes mellitus) 20 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Hans-Georg Joost, German Institute of Human Nutrition, Nuthetal, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved (...) Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Insulin glargin/Lixisenatid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 May 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) the Fridericia formula R AC Accumulation ratio RH relative humidity RQ (Environmental) Risk Quotient SBP systolic blood pressure SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics TAMC total aerobic microbial count TYMC total combined yeasts/moulds count T2DM type 2 diabetes mellitus t max time to C max UGE urinary glucose excretion UGT uridine 5’-diphospho-glucuronosyltransferase ULN upper limit of normal UV ultraviolet UV-Vis ultraviolet

2018 European Medicines Agency - EPARs

5. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products (...) diabetes mellitus TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin T max time to C max TYMC total combined yeasts/moulds count UGE urinary gluclose excretion UGT uridine 5’-diphospho-glucuronosyltransferase UK United Kingdom UKPDS United Kingdom Prospective Diabetes Study ULN upper limit of normal US United States UV ultraviolet UV-Vis ultraviolet-visible Assessment report EMA/86941/2018 Page 7/139 1. Background information on the procedure 1.1. Submission of the dossier The applicant

2018 European Medicines Agency - EPARs

6. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use (...) analysis plan SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics SMQ Standard MedDRA Query SOC System organ class T2DM type 2 diabetes mellitus TAMC total aerobic microbial count Tmax time to first occurrence of maximum observed concentration TYMC total combined yeasts/moulds count UGE urinary glucose excretion ULN upper limit of normal US United States USPI United States Prescribing Information UTI urinary tract infection UV ultraviolet

2018 European Medicines Agency - EPARs

7. Study Protocol for the Effects of Artificial Intelligence (AI)-Supported Automated Nutritional Intervention on Glycemic Control in Patients with Type 2 Diabetes Mellitus. Full Text available with Trip Pro

Study Protocol for the Effects of Artificial Intelligence (AI)-Supported Automated Nutritional Intervention on Glycemic Control in Patients with Type 2 Diabetes Mellitus. Nutritional intervention is effective in improving glycemic control in patients with type 2 diabetes but requires large inputs of manpower. Recent improvements in photo analysis technology facilitated by artificial intelligence (AI) and remote communication technologies have enabled automated evaluations of nutrient intakes (...) controlled study comparing the efficacy of AI-supported automated nutrition therapy with that of conventional human nutrition therapy in patients with type 2 diabetes. Patients with type 2 diabetes mainly controlled with diet are to be recruited and randomly assigned to AI-supported nutrition therapy (n = 50) and to human nutrition therapy (n = 50). Asken, a mobile application whose nutritional evaluation has been already validated to that by the classical method of weighted dietary records, has been

2019 Diabetes therapy : research, treatment and education of diabetes and related disorders Controlled trial quality: uncertain

8. Effects of nutritional nursing intervention based on glycemic load for patient with gestational diabetes mellitus. Full Text available with Trip Pro

Effects of nutritional nursing intervention based on glycemic load for patient with gestational diabetes mellitus. To determine the effects of nutritional nursing intervention based on glycemic load (GL) for patients with gestational diabetes mellitus.One hundred thirty-four patients diagnosed with gestational diabetes mellitus at our hospital were selected from March 2015 to March 2017 and randomly divided into the observation (n = 67) and control groups (n = 67). All of the patients (...) , eclampsia, preg- nancy hypertension syndrome, and fetal distress in the observation group.Nutritional nursing intervention based on GL is more effective than traditional nutritional nursing for patients with gestational diabetes, and can effectively control the blood glucose level, reduce the incidence of pregnant complica- tions, and improve the pregnancy outcome. Thus, nutritional nursing intervention based on GL deserves to be popularized.

2019 Ginekologia polska Controlled trial quality: uncertain

9. Dapagliflozin (Forxiga) - type 1 diabetes mellitus

Dapagliflozin (Forxiga) - type 1 diabetes mellitus 1 Published 9 September 2019 1 SMC2185 dapagliflozin 5mg film coated tablets (Forxiga®) AstraZeneca UK Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission dapagliflozin (Forxiga®) is accepted for use within NHSScotland (...) . Indication under review: In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI =27kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. Dapagliflozin in combination with insulin improved glycaemic control compared with insulin alone in adult patients with inadequately controlled type 1 diabetes. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication

2019 Scottish Medicines Consortium

10. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

(95% CI, 1.51–2.28) Similar in men and women … Retrospective cohort of Kaiser Permanente Northwest Database 8231 +DM, 8845 no DM Up to 6 rates (person-years): DM: 30.9/1000 No DM: 12.4/1000 Rate ratio, 2.5 (95% CI, 2.3–2.7) … … CAD indicates coronary artery disease; DM, diabetes mellitus; ellipses (…), not reported; HF, heart failure; HR, hazard ratio; MESA, Multi-Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Examination Survey; and RR, relative risk. The risk of HF (...) million adults in the United States have type 2 diabetes mellitus (DM), whereas 6.5 million have heart failure (HF), and both conditions are expected to continue to increase in prevalence over time. Although DM and HF are each individually associated with considerable morbidity and mortality, they often occur together, which further worsens adverse patient outcomes, quality of life, and costs of care. Identifying and implementing optimal treatment strategies for patients living with DM and HF

2019 American Heart Association

11. Insulin aspart (Fiasp) - Diabetes Mellitus

Insulin aspart (Fiasp) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 10 November 2016 EMA/CHMP/50360/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Fiasp International non-proprietary name: insulin aspart Procedure No. EMEA/H/C/004046/0000 Note Assessment report as adopted (...) of diabetes mellitus in adults Pharmaceutical form(s): Solution for injection Strength(s): 100 U/ml Route(s) of administration: Intravenous use, Subcutaneous use Packaging: cartridge (glass) (Penfill), pre-filled pen (glass) (FlexTouch) and vial (glass) Package size(s): 10 cartridges, 5 cartridges, 1 pre-filled pen, 1 pre-filled pen + 7 NovoFine Plus needles, 1 pre-filled pen + 7 NovoFine needles, 1 pre-filled pen + 7 NovoTwist needles, ), 5 pre-filled pens, 10 (2 x 5) pre-filled pens (multipack), 1 vial

2017 European Medicines Agency - EPARs

12. Adult Type 1 diabetes mellitus

Adult Type 1 diabetes mellitus Adult type 1 diabetes mellitus National Clinical Guideline No. 17 National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar June 2018This National Clinical Guideline for adults with type 1 diabetes has been developed by the Guideline Development Group, supported by the HSE National Clinical Programme for Diabetes. Part of the process of developing this guideline involved contextualising (for Ireland) the National Institute for Health and Care (...) guidance © NICE (2015) Type 1 diabetes in adults: diagnosis and management. Available from https://www.nice.org.uk/guidance/ng17 All rights reserved. Subject to Notice of rights . NICE guidance is prepared for the National Health Service in England. It is subject to regular review and updating and may be withdrawn. NICE accepts no responsibility for the use of its content in this publication. Citation text Department of Health (2018) Adult type 1 diabetes mellitus (NCEC National Clinical Guideline

2018 National Clinical Guidelines (Ireland)

13. National Clinical Guideline on Adult type 1 diabetes mellitus

National Clinical Guideline on Adult type 1 diabetes mellitus Adult type 1 diabetes mellitus National Clinical Guideline No. 17 National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar June 2018This National Clinical Guideline for adults with type 1 diabetes has been developed by the Guideline Development Group, supported by the HSE National Clinical Programme for Diabetes. Part of the process of developing this guideline involved contextualising (for Ireland) the National (...) This guideline draws on NICE guidance © NICE (2015) Type 1 diabetes in adults: diagnosis and management. Available from https://www.nice.org.uk/guidance/ng17 All rights reserved. Subject to Notice of rights . NICE guidance is prepared for the National Health Service in England. It is subject to regular review and updating and may be withdrawn. NICE accepts no responsibility for the use of its content in this publication. Citation text Department of Health (2018) Adult type 1 diabetes mellitus (NCEC National

2018 HIQA Guidelines

14. Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin

monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Project ID: OTJA08 This report is part of the project / joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020) Continuous (real-time) and flash glucose monitoring as personal, standalone systems in patients with DM treated with insulin Version 1.4, 27 July 2018 EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date (...) ) as personal, standalone systems in patients with diabetes mellitus treated with insulin. Joint Assessment. Zagreb: EUnetHTA; 2018. Report No.: OTJA08. The document is available on the website of EUnetHTA. Continuous (real-time) and flash glucose monitoring as personal, standalone systems in patients with DM treated with insulin Version 1.4, 27 July 2018 EUnetHTA Joint Action 3 WP4 4 TABLE OF CONTENTS LIST OF ABBREVIATIONS 7 GLOSSARY 10 SUMMARY 12 SCOPE 12 INTRODUCTION 12 METHODS 15 RESULTS 16 SUMMARY

2018 EUnetHTA

15. [The effect of nutrition intervention on the body composition and blood glucose in newly diagnosed patients with type 2 diabetes mellitus complicated with overweight and obesity]. (Abstract)

[The effect of nutrition intervention on the body composition and blood glucose in newly diagnosed patients with type 2 diabetes mellitus complicated with overweight and obesity]. Objective: To study the effect of nutrition intervention on the body composition and blood glucose in newly diagnosed patients with type 2 diabetes mellitus complicated with overweight and obesity. Methods: A total of 84 newly diagnosed patients with type 2 diabetes mellitus complicated with overweight and obesity (...) loss (P<0.05). Conclusion: The three-month nutrition intervention could change the dietary habit and components of patients with type 2 diabetes mellitus by reducing the blood glucose, body fat rate and visceral fat index significantly. The degree of reduced BMI is positively related to the decrease of fasting blood glucose and postprandial blood glucose.

2018 Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

16. Medical nutrition therapy for gestational diabetes mellitus based on Mediterranean Diet principles: a subanalysis of the St Carlos GDM Prevention Study Full Text available with Trip Pro

Medical nutrition therapy for gestational diabetes mellitus based on Mediterranean Diet principles: a subanalysis of the St Carlos GDM Prevention Study To assess whether Mediterranean Diet (MedDiet)-based medical nutrition therapy facilitates near-normoglycemia in women with gestational diabetes mellitus (GDMw) and observe the effects on adverse pregnancy outcomes.This is a secondary analysis of the St Carlos GDM Prevention Study, conducted between January and December 2015 in Hospital Clínico (...) San Carlos (Madrid, Spain). One thousand consecutive women with normoglycemia were included before 12 gestational weeks (GWs), with 874 included in the final analysis. Of these, 177 women were diagnosed with gestational diabetes mellitus (GDM) and 697 had normal glucose tolerance. All GDMw received MedDiet-based medical nutrition therapy with a recommended daily extra virgin olive oil intake ≥40 mL and a daily handful of nuts. The primary goal was comparison of hemoglobin A1c (HbA1c) levels at 36

2018 BMJ open diabetes research & care

17. Factors Influencing Mobility Relative to Nutritional Status among Elderly Women with Diabetes Mellitus Full Text available with Trip Pro

Factors Influencing Mobility Relative to Nutritional Status among Elderly Women with Diabetes Mellitus The prevalence of functional disability is very high among elderly people. Malnourished individuals are less likely to recover from limited mobility and have higher risk of deterioration of functional disability. This study investigated factors influencing mobility relative to nutritional status in elderly women with diabetes mellitus.We analyzed data of 464 elderly women with diabetes (...) ; the explanatory power of this model was 40.5% (F=16.589; P<0.001).The level of mobility relative to nutritional status varied widely among elderly women with diabetes mellitus. Therefore, to improve mobility in malnourished elderly people, public health nurses must provide comprehensive nutrition management and a support system in addition to physical and psychological interventions.

2018 Iranian journal of public health

18. Trends in the management levels of metabolic risk factors in middle-aged and elderly patients with type 2 diabetes mellitus: The Korean National Health and Nutrition Examination Survey 1998-2014. Full Text available with Trip Pro

Trends in the management levels of metabolic risk factors in middle-aged and elderly patients with type 2 diabetes mellitus: The Korean National Health and Nutrition Examination Survey 1998-2014. The present study examined the temporal trends in the management of blood pressure, glucose, and lipid levels among middle-aged and elderly patients with type 2 diabetes using data from the Korean National Health and Nutrition Examination Survey (1998-2014). A total of 3,689 patients with diabetes were (...) groups during 1998-2014, although no trends were observed for lipid levels. Based on the most recent survey, approximately 50% of patients with diabetes had hyperglycemia, and one-third of patients with diabetes and hypertension did not appropriately manage their blood pressure. In addition, 50% of the patients in both age groups did not manage their lipid profiles, and the management of lipid profiles did not improve in recent years. These results suggest that continuous follow-up is needed

2017 PLoS ONE

19. Effects of nutrition motivational intervention in patients affected by type 2 diabetes mellitus: a longitudinal study in Naples, South Italy. Full Text available with Trip Pro

Effects of nutrition motivational intervention in patients affected by type 2 diabetes mellitus: a longitudinal study in Naples, South Italy. Type 2 diabetes (T2D) is associated with a prion diminished quality of life, especially due to the severe complications that it implicates. Changing dietary habits is an absolute priority, as well as implementing nutritional motivational programs. The aim of this study was to verify the effectiveness of a nutritional intervention in improving the health (...) circumference, as well as in glycaemic values (p = 0.018).A nutritional motivational intervention may be useful in improving dietary habits and health status of patients with T2D. We hope that a similar intervention will be applied in Campania and in other Italian regions.Registration number is ISRCTN11067689 ; date of registration: 10/09/2018. Retrospectively registered.

2018 BMC Public Health

20. Association between muscle strength and type 2 diabetes mellitus in adults in Korea: Data from the Korea national health and nutrition examination survey (KNHANES) VI. Full Text available with Trip Pro

Association between muscle strength and type 2 diabetes mellitus in adults in Korea: Data from the Korea national health and nutrition examination survey (KNHANES) VI. Diabetes mellitus (DM) is a significant chronic disease, and health burden from DM is increasing. Recently, studies on the relationship between handgrip strength, which is a measuring tool for muscle strength, and type 2 DM were published. However, the results have been conflicting. In addition, few studies that used data from (...) adults in Korea have been conducted. Thus, this study aimed to identify the association between handgrip strength as well as type 2 DM and insulin resistance in adults using data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2014 to 2015. Inflammation is a condition affecting the muscle strength of individuals with type 2 DM; therefore, its mediating effects were also examined.We included 8208 participants aged between 19 and 80 years who had undergone a handgrip test

2018 Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>